478 related articles for article (PubMed ID: 34776414)
1. A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities.
Nekoukar Z; Moghimi M; Salehifar E
Blood Res; 2021 Dec; 56(4):229-242. PubMed ID: 34776414
[TBL] [Abstract][Full Text] [Related]
2. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
[TBL] [Abstract][Full Text] [Related]
3. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
4. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
5. Management of chronic myeloid leukemia in 2023 - common ground and common sense.
Senapati J; Sasaki K; Issa GC; Lipton JH; Radich JP; Jabbour E; Kantarjian HM
Blood Cancer J; 2023 Apr; 13(1):58. PubMed ID: 37088793
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
McCormack PL; Keam SJ
BioDrugs; 2012 Feb; 26(1):61-4. PubMed ID: 22233429
[TBL] [Abstract][Full Text] [Related]
7. Targeted drugs in chronic myeloid leukemia.
Gora-Tybor J; Robak T
Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
[TBL] [Abstract][Full Text] [Related]
9. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.
McCormack PL; Keam SJ
Drugs; 2011 Sep; 71(13):1771-95. PubMed ID: 21902298
[TBL] [Abstract][Full Text] [Related]
11. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
12. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
Jabbour E; Kantarjian H
Am J Hematol; 2012 Nov; 87(11):1037-45. PubMed ID: 23090888
[TBL] [Abstract][Full Text] [Related]
13. A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1
Gleixner KV; Sadovnik I; Schneeweiss M; Eisenwort G; Byrgazov K; Stefanzl G; Berger D; Herrmann H; Hadzijusufovic E; Lion T; Valent P
Leuk Res; 2019 Mar; 78():36-44. PubMed ID: 30711891
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib in chronic myeloid leukemia: a review.
Aguilera DG; Tsimberidou AM
Ther Clin Risk Manag; 2009 Apr; 5(2):281-9. PubMed ID: 19536317
[TBL] [Abstract][Full Text] [Related]
15. Contemporary treatment methods of adult patients with BCR/ABL1 positive chronic myeloid leukemia.
Slezáková K; Mistrík M; Bátorová A
Vnitr Lek; 2020; 66(4):214-224. PubMed ID: 32972178
[TBL] [Abstract][Full Text] [Related]
16. Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis.
Kronick O; Chen X; Mehra N; Varmeziar A; Fisher R; Kartchner D; Kota V; Mitchell CS
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686630
[TBL] [Abstract][Full Text] [Related]
17. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
Jabbour E; Kantarjian H; Cortes J
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):323-34. PubMed ID: 25971713
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors.
Weatherald J; Bondeelle L; Chaumais MC; Guignabert C; Savale L; Jaïs X; Sitbon O; Rousselot P; Humbert M; Bergeron A; Montani D
Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32527740
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.
Jabbour E; Cortes J; Kantarjian H
Cancer; 2011 Mar; 117(5):897-906. PubMed ID: 20945321
[TBL] [Abstract][Full Text] [Related]
20. Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies.
Cheng F; Xu Q; Li Q; Cui Z; Li W; Zeng F
Front Oncol; 2023; 13():1113462. PubMed ID: 36814818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
